Double-blind comparison of single doses of DS103-282, baclofen and placebo for suppression of spasticity.
Open Access
- 1 December 1980
- journal article
- research article
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
- Vol. 43 (12) , 1132-1136
- https://doi.org/10.1136/jnnp.43.12.1132
Abstract
Twelve spastic patients received single oral doses of a new anti-spastic drug DS103-282 (Sandoz) 6 mg, baclofen 20 mg, and placebo on three separate days. Passive stretch responses were measured before administration and for four hours afterwards. DS103-282 was more effective than baclofen, and both drugs were more effective than placebo. Analysis of the recordings confirmed that DS103-282 had a specific effect upon stretch reflexes independent of its effect on resting muscle tone. Its action appeared at 30 to 45 minutes after ingestion, with maximum activity at 60-90 minutes. Unwanted effects of DS103-282 were drowsiness and (in one case) potentiation of antihypertensive therapy.Keywords
This publication has 3 references indexed in Scilit:
- The pharmacology of 5-chloro-4-(2-imidazolin-2-yl-amino)-2,1,3-benzothiadiazole (DS 103-282), a novel myotonolytic agent.1980
- Time course of clinical and physiological effects of stimulation of the cerebellar surface in patients with spasticity.Journal of Neurology, Neurosurgery & Psychiatry, 1978
- [Clinical experiences with a new muscle relaxant (DS 103-282 Sandoz) (author's transl)].1977